Cardiac Pathways' strategy is to develop solutions for the most difficult cardiac rhythm problems, those for which even palliative treatments are limited. Armed with promising advanced technology, the company was one of the last through the 1996 medical device IPO window but since then has been paying the price for being slow to market. With FDA approval finally in hand, along with new management and additional financing obtained at a premium cost, Cardiac Pathways hopes to sustain itself long enough to finally take advantage of its technological lead by creating a new market treating patients who have few other options.
by Stephen Levin
You're a senior health care executive approached for the first time with an opportunity to become a president and CEO....
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
For months, US Health and Human Services Secretary Robert F. Kennedy Jr. had talked about banning direct-to-consumer television ads for prescription drugs. And now, he is making good on his promise – but in a roundabout way.
Early commercial successes are proving the value of digital twins, yet regulatory uncertainty and cultural resistance continue to limit widespread uptake across biopharma.
The gap between investor returns and patient returns is precisely that which the SALY/SADY framework is designed to fill.
Charles River's chief scientific officer Julie Frearson discusses how the agency's embrace of artificial intelligence is driving a fundamental shift in how companies must structure and manage their research data
The rapid growth of Chinese biopharmas has led to increased dealmaking with the US and Europe, but that could be stifled by a potential new Trump Administration policy.
Seven $1bn+ alliances were penned in August, and two exceeded $2bn.
With drug pricing policies potentially squeezing industry margins, companies are increasingly turning to AI-driven trial optimization to rescue sub-optimal studies and accelerate development timelines.
